Andrew D. Dickinson serves as the Chief Financial Officer (CFO) at Gilead Sciences Inc., a biopharmaceutical company focused on developing innovative therapies for life-threatening diseases. In his role, Dickinson is responsible for overseeing the company's financial strategy, planning, and operations, ensuring Gilead's continued growth and financial health. His leadership has been instrumental in guiding the company through complex financial landscapes and supporting its mission to advance healthcare globally. Before joining Gilead Sciences, Dickinson held several high-level financial positions that honed his expertise in the industry. He previously served as the CFO of Amgen Inc., another leading biotechnology company, where he played a key role in driving the company's financial performance and strategic initiatives. His tenure at Amgen was marked by significant achievements, including the successful launch of several blockbuster drugs and the implementation of cost-saving measures that enhanced the company's profitability. Prior to Amgen, Dickinson worked at Eli Lilly and Company, where he gained extensive experience in financial management and corporate strategy. Dickinson's professional background is complemented by his strong academic credentials, with a degree in finance and accounting from a prestigious university. His strategic vision and financial acumen have made him a respected figure in the biopharmaceutical industry. At Gilead Sciences, he continues to lead with a focus on sustainable growth and innovation, ensuring that the company remains at the forefront of medical advancements while maintaining robust financial performance.